Practical Neurology

New long-term data presented at 2026 provide insight into sustained disease control and treatment burden with ( ) treatment in adults with AChR+ generalized .
https://ow.ly/hYFQ50ZUavY
UCB USA American Association of Neuromuscular & Electrodiagnostic Medicine - AANEM American Academy of Neurology (AAN) Myasthenia Gravis Foundation of America, Inc.

Data Presented at AANEM 2026 Highlight Sustained Symptom Control and High Adherence for Participants with gMG Treated With Zilbrysq KEY TAKEAWAYS Participants reported taking 99.2% of expected zilucoplan doses during the RAISE-XT open-label extension, providing feasibility data for long-term daily self-administration. Nearly 30% of patients receiving nonsteroidal immunosuppres…

Phase 4 data presented at 2026 suggest that people with can transition directly from IVIG to subcutaneous efgartigimod while maintaining stable disease control.

https://ow.ly/3yXL50ZU4j2

American Association of Neuromuscular & Electrodiagnostic Medicine - AANEM argenxglobal American Academy of Neurology (AAN)

87% of Patients With CIDP Transitioned From IVIG to Subcutaneous Efgartigimod in Phase 4 Study KEY TAKEAWAYS Most individuals with CIDP continued treatment with subcutaneous efgartigimod for 12 weeks after transitioning directly from IVIG. CIDP disease severity remained stable after the switch, and 56.5% of patients reported improvement a…

The American Heart Association and American Stroke Association have published an updated guideline for rehabilitation and recovery in adults with .
https://ow.ly/MGmz50ZTKf7
Stroke AHA/ ASA Endovascular Today

AHA/ASA Updates Guidance for Adult Stroke Rehabilitation and Recovery KEY TAKEAWAYS The updated AHA/ASA guideline frames stroke rehabilitation as a longitudinal process, emphasizing coordinated multidisciplinary care and repeated reassessment across recovery. Key updates address technology-enabled rehabilitation, me…

How are new technologies changing programming for people with 's?

Aparna Wagle Shukla, MD, explores directional stimulation, neural sensing, imaging, adaptive , and more in an article.
https://ow.ly/Cgsu50ZTi4q
International Parkinson and Movement Disorder Society Parkinson's Foundation The Michael J. Fox Foundation for Parkinson's Research University of Florida

The New Era of Deep Brain Stimulation Programming in Parkinson Disease Directional stimulation, image-guided programming, neural sensing, adaptive DBS, and remote programming are making deep brain stimulation programming more…

Phase 3 ADAPT OCULUS data presented at 2026 showed continued improvement in patient-reported ocular symptoms with additional treatment cycles in people with ocular .
https://ow.ly/S68G50ZThVx
Myasthenia Gravis Foundation of America, Inc. ArgenX American Academy of Neurology (AAN)

Continued Efgartigimod Treatment in Adults With Ocular Myasthenia Gravis Linked to Further Symptom Improvement KEY TAKEAWAYS In phase 3 data from the ADAPT OCULUS study, participants with ocular myasthenia gravis treated with additional cycles of subcutaneous efgartigimod beyond the placebo-controlled period showed continued improvement in symptoms. Mean p…

Mount Sinai and Cerenovus entered a collaborative research agreement to evaluate an investigational liquid approach for the treatment of people with brain .
https://ow.ly/iZ2a50ZSRyv
Icahn School of Medicine at Mount Sinai Society for Neuro-Oncology, USA American Academy of Neurology (AAN) Johnson & Johnson

Mount Sinai, Johnson & Johnson Partner to Study Targeted Radioembolization for Brain Tumors KEY TAKEAWAYS Mount Sinai and Cerenovus, a Johnson & Johnson company, entered a collaborative research agreement to evaluate an investigational liquid radioembolic approach for the treatment of people with brain tumors. The strategy combines i…

The U.S. Food and Drug Administration has approved ( ), a selective dopamine D1/D5 receptor agonist, for the treatment of adults with disease.
https://ow.ly/rCTr50ZSqkC
AbbVie Parkinson's Foundation The Michael J. Fox Foundation for Parkinson's Research American Academy of Neurology (AAN) International Parkinson and Movement Disorder Society

Tavapadon Treatment for Adults With Parkinson Disease Approved by FDA KEY TAKEAWAYS The FDA approved tavapadon, a selective dopamine D1/D5 receptor agonist, for the treatment of adults with Parkinson disease. The approval is supported by the phase 3 TEMPO program, which evaluated tavapadon treatment as a monotherapy…

The U.S. Food and Drug Administration has granted Orphan Drug Designation to , an investigational treatment for people with stiff person syndrome.
https://ow.ly/ogU350ZREhj
The Stiff Person Syndrome Research Foundation American Association of Neuromuscular & Electrodiagnostic Medicine - AANEM American Academy of Neurology (AAN)

FDA Grants Orphan Drug Designation to Qivigy for People With Stiff Person Syndrome KEY TAKEAWAYS The FDA granted Orphan Drug Designation to Qivigy for the treatment of people with stiff person syndrome, a rare immune-mediated neurologic disorder. Qivigy was previously approved for adults with primary humoral immunodeficiency. …

Xenon Pharmaceuticals submitted a New Drug Application to the U.S. Food and Drug Administration for as a potential treatment for people with focal .
https://ow.ly/x5ta50ZREf2
Xenon Pharmaceuticals pvt.ltd American Epilepsy Society American Academy of Neurology (AAN)

Xenon Pharmaceuticals Submits New Drug Application to FDA for Azetukalner for the Treatment of People with Focal Seizures KEY TAKEAWAYS Xenon Pharmaceuticals submitted an NDA to the FDA for azetukalner as a potential treatment for people with focal seizures. The submission is supported by results of the phase 2b X-TOLE and phase 3 X-TOLE2 studies. Ongoing phase 3 e…

( ) was approved by the U.S. Food and Drug Administration for the treatment of adults and pediatric patients with - who weigh at least 15 kg.
https://ow.ly/LGpu50ZRE7B
National Ataxia Foundation IntraBio Inc International Parkinson and Movement Disorder Society American Academy of Neurology (AAN)

FDA Approves Aqneursa as First Treatment for People With Ataxia-Telangiectasia KEY TAKEAWAYS The FDA approved Aqneursa for ataxia in adults and children with ataxia-telangiectasia who weigh at least 15 kg. Approval was supported by a phase 3 crossover trial in which treatment with Aqneursa was associated with improvement o…